Altogether, the clinical manifestations (i.e. growth impairment, elevated IgE, eczema) suggest variability in penetrance of the mutant genotypes and are consistent with the milder phenotype of AD STAT5B loss-of-function mutations (Supplementary Table 2 and Supplementary Fig. 2). This evidence concerns the gene STAT5B and Alzheimer disease.